Zinpentraxin alfa

Extended indication	Idiopathic Pulmonary Fibrosis (IPF)
Therapeutic value	No estimate possible yet
Registration phase	No registration expected

Product

Active substance	Zinpentraxin alfa
Domain	Lung diseases
Reason of inclusion	New medicine (specialité)
Main indication	Lung diseases other
Extended indication	Idiopathic Pulmonary Fibrosis (IPF)
Manufacturer	Roche
Portfolio holder	Roche
Route of administration	Intravenous
Therapeutical formulation	Intravenous drip
Budgetting framework	Intermural (MSZ)
Additional remarks	A recombinant form of human pentraxin-2 protein able to regulate monocytes and macrophages at areas of tissue damage to prevent and reverse fibrosis.

Registration route	Centralised (EMA)
ATMP	No
Submission date	2024
Expected Registration	2025
Orphan drug	Yes
Registration phase	No registration expected
Additional remarks	De fabrikant geeft aan niet langer registratie te verwachten van dit product.

Therapeutic value	No estimate possible yet
Frequency of administration	1 times every 4 weeks
Dosage per administration	10 mg/kg
References	NCT04594707, NCT04552899

Patient volume	< 2,040 Market share is generally not included unless otherwise stated.
References	Jaarverslag Longfibrosepatiëntenvereniging 2017 (1)
Additional remarks	Er zijn ongeveer 3.400 longfibrose patiënten in Nederland 60% daarvan heeft IPF. Dit komt neer op 2.040 IPF patiënten.

Patient volume

< 2,040

Market share is generally not included unless otherwise stated.

References

Jaarverslag Longfibrosepatiëntenvereniging 2017 (1)

Additional remarks

Er zijn ongeveer 3.400 longfibrose patiënten in Nederland 60% daarvan heeft IPF. Dit komt neer op 2.040 IPF patiënten.

There is currently nothing known about the expected cost.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently no futher information available.